253 related articles for article (PubMed ID: 32026050)
1. Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z; Parkes A
Curr Treat Options Oncol; 2020 Feb; 21(2):15. PubMed ID: 32026050
[TBL] [Abstract][Full Text] [Related]
2. Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
Zhou MY; Bui NQ; Charville GW; Ganjoo KN; Pan M
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298520
[TBL] [Abstract][Full Text] [Related]
3. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
4. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.
Thirasastr P; Somaiah N
Ther Adv Med Oncol; 2022; 14():17588359221081073. PubMed ID: 35251319
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
[TBL] [Abstract][Full Text] [Related]
6. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
7. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
9. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
10. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma.
Kobayashi A; Sakuma T; Fujimoto M; Jimbo N; Hirose T
Appl Immunohistochem Mol Morphol; 2019; 27(10):758-763. PubMed ID: 31145104
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Thirasastr P; Lin H; Amini B; Wang WL; Cloutier JM; Nassif EF; Keung EZ; Roland CL; Feig B; Araujo D; Benjamin RS; Conley AP; Livingston JA; Ludwig J; Patel S; Ratan R; Ravi V; Zarzour MA; Zhou X; Somaiah N
Cancer Med; 2023 Feb; 12(4):4282-4293. PubMed ID: 36151848
[TBL] [Abstract][Full Text] [Related]
13. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
[TBL] [Abstract][Full Text] [Related]
15. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
[TBL] [Abstract][Full Text] [Related]
16. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
Matsuda S; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
[TBL] [Abstract][Full Text] [Related]
17. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological therapies for Liposarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):361-377. PubMed ID: 28135854
[TBL] [Abstract][Full Text] [Related]
19. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
[TBL] [Abstract][Full Text] [Related]
20. Application of molecular biology to individualize therapy for patients with liposarcoma.
Abbas Manji G; Singer S; Koff A; Schwartz GK
Am Soc Clin Oncol Educ Book; 2015; ():213-8. PubMed ID: 25993159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
